Skip to Content


Damian Garde and Meg Kesh, featuring Rachel Sachs (Academic Fellow alumna)
STAT
October 12, 2016

Read the full post

From the post:

How? Washington University law professor Rachel Sachs and Department of Veterans Affairs economist Austin Frakt suggest tying drug prices to cost-effectiveness. They'd also like society to pay more for preventive treatments and cures and less for lifelong treatments for chronic disease, in a bid to goad the industry to focus on developing treatments with more public benefit.

Read the full post here

Read the full post

Tags

fda   health law policy   pharmaceuticals   public health   regulation